Watchlist Price Alert

Biohaven Ltd. (BHVN)

NYSE: BHVN · Real-Time Price · USD

15.94

-0.08 (-0.50%)

At close: May 19, 2025, 2:59 PM

-0.50% (1D)

Bid	15.89
Market Cap	1.63B
Revenue (ttm)	n/a
Net Income (ttm)	-888.6M
EPS (ttm)	-9.25
PE Ratio (ttm)	-1.72
Forward PE	-2.71
Analyst	Buy

Ask	15.97
Volume	1,161,126
Avg. Volume (20D)	1,783,577
Open	15.45
Previous Close	16.02
Day's Range	15.22 - 16.89
52-Week Range	14.69 - 55.70
Beta	4.18

About BHVN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BHVN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BHVN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Biohaven has released their quartely earnings on May 12, 2025:

Revenue of $0 misses estimates by $1.39M, with NaN% YoY growth.

EPS of -1.64 misses estimates by -0.15, with 7.34% YoY growth.

Why Price Moved

4 days ago

-19.53%

Biohaven shares are trading lower after the FDA's ... Unlock content with Pro Subscription

5 days ago

-5.11%

Biohaven shares are trading lower after the company reported a Q1 adjusted EPS miss.

News

3 days ago · accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).

4 days ago · fool.com

Why Biohaven Stock Dove by Nearly 20% on Thursday

Volatile biotech stock Biohaven (BHVN -19.41%) is prone to sharp movements both up and down. On Thursday, it had one of its down days, with its share price eroding by almost 20% on a development with ...

4 days ago · benzinga.com

Why Is Biohaven Stock Falling On Thursday?

Biohaven Ltd. BHVN shares plunged on Thursday after the Food and Drug Administration (FDA) unexpectedly delayed the review date for its rare-disease drug troriluzole.

1 week ago · seekingalpha.com

Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict

BHVN's lead asset is Troriluzole, which is nearing a pivotal FDA decision by August 2025. The company also recently secured an additional $600 million financing through secured notes with Oberland Cap...

3 weeks ago · fool.com

Why BioHaven Stock Is Soaring Today

Shares of Biohaven (BHVN 5.24%) are surging on Monday. The company's stock was up about 8% as of midday trading and had climbed as much as 10% earlier in the day.

3 weeks ago · fool.com

Why Biohaven Stock Plummeted by More Than 15% Today

On Friday's news that Biohaven (BHVN -15.34%) withdrew its application for a top investigational drug from an important regulator, investors aggressively traded out of the stock. The clinical-stage bi...

1 month ago · businesswire.com

BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm.

1 month ago · fool.com

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March

Shares of early-stage biotech stocks, including Biohaven (BHVN -6.50%), Recursion Pharmaceuticals (RXRX -4.92%), and CRISPR Therapeutics (CRSP -2.05%), plunged in March, with the stocks down 35.3%, 29...

1 month ago · accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN

NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE:BHVN). Such investors are advised to c...

1 month ago · accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bronstein, Gewirtz & Grossman, LLC (BHVN) and Encourages Stockholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN...

Load More News